Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains - Case, James Brett; Mackin, Samantha; Errico, John M.; Chong, Zhenlu; Madden, Emily A.; Whitener, Bradley; Guarino, Barbara; Schmid, Michael A.; Rosenthal, Kim; Ren, Kuishu; Dang, Ha V.; Snell, Gyorgy; et al. (Nature communications, 2022)
Keywords: 13; 13/1; 13/106; 13/31; 631/250/2152/2153/1291; 631/326/596/4130; 64; 64/60; 82/1; 82/103; ACE2; Angiotensin-converting enzyme 2; Animals; Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal - therapeutic use; Antibodies, Neutralizing; Antibodies, Viral - therapeutic use; Biotechnology; Bronchopulmonary infection; Cell culture; Correlation analysis; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Glycoprotein S; Glycoproteins; Humanities and Social Sciences; Humans; Immunotherapy; Infections; Lungs; Membrane Glycoproteins; Mice; Monoclonal antibodies; multidisciplinary; Mutation; Neutralization; Neutralization Tests; Neutralizing; Resilience; SARS-CoV-2; Science; Science (multidisciplinary); Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus; Spike protein; Transgenic mice; Viral diseases; Viral Envelope Proteins